Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciclesonide - AstraZeneca/Covis Pharma/Takeda

Next Previous
X
Search
Drug Profile

Ciclesonide - AstraZeneca/Covis Pharma/Takeda

Alternative Names: Alvesco; Alvesco HFA; BTR-15; BTR-15K; BY 9010; Ciclesonide DPI; Ciclesonide I.S.; Ciclesonide pMDI; EL 876; Omnair; Omnaris; Omnaris HFA; RPR 251526; TBN-15; XRP 1526; Zetonna

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nycomed
  • Developer Covis Pharma; Sumitomo Pharma America; Takeda; Takeda Pharmaceuticals International GmbH; Teijin Pharma
  • Class Antiallergics; Antiasthmatics; Antivirals; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic rhinitis; Asthma; Perennial allergic rhinitis; Seasonal allergic rhinitis
  • Phase III COVID 2019 infections

Most Recent Events

  • 09 Feb 2023 Ciclesonide is still in phase III trial for COVID-2019 infections (In children, In adolescents, In adults, In the elderly) in USA, United Kingdom, Australia, South Korea, Sweden, Japan (Inhalation) (NCT04377711)
  • 15 Apr 2021 Efficacy and adverse events data from phase III trial in COVID-2019 infections released by Covis Pharma
  • 05 Jan 2021 Covis Pharma completes a phase III trial for COVID-2019 infections (In children, In adolescents, In adults, In the elderly) in USA, United Kingdom, Australia, South Korea, Sweden, Japan (Inhalation) (NCT04377711)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top